Cost of Revenue Trends: Perrigo Company plc vs MiMedx Group, Inc.

Comparing cost trends of Perrigo and MiMedx from 2014 to 2023.

__timestamp	MiMedx Group, Inc.	Perrigo Company plc
Wednesday, January 1, 2014	12665000	2613100000
Thursday, January 1, 2015	20202000	2891500000
Friday, January 1, 2016	32407000	3228800000
Sunday, January 1, 2017	35219000	2966700000
Monday, January 1, 2018	36386000	2900200000
Tuesday, January 1, 2019	43081000	3064100000
Wednesday, January 1, 2020	39330000	3248100000
Friday, January 1, 2021	43283000	2722500000
Saturday, January 1, 2022	48316000	2996200000
Sunday, January 1, 2023	54634000	2975200000

Unlocking the unknown

Cost of Revenue Trends: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotech industries, understanding cost dynamics is crucial. Perrigo Company plc, a global leader in over-the-counter health products, and MiMedx Group, Inc., a pioneer in regenerative medicine, offer a fascinating study in contrasts. From 2014 to 2023, Perrigo's cost of revenue has shown a relatively stable trend, averaging around $3 billion annually, with a slight dip in 2021. In contrast, MiMedx has experienced a more dynamic growth, with costs increasing by over 330% from 2014 to 2023. This reflects MiMedx's aggressive expansion and innovation strategies. The data highlights the differing operational scales and market strategies of these two companies, providing valuable insights for investors and industry analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025